Researchers from the Broad Institute and Novartis used RNA interference to generate catalogs of genes that cancer cells rely on to grow and survive.

Parent firm Gene by Gene calls the law "brief and vague" and is pushing for ancestry testing to be exempt from the provision of the genetic privacy statute.

Researchers developed a gene expression-based classifier for four gastric cancer subtypes and found that some are associated with better outcomes than others.

Scientists reported this week for the first time a Danish reference genome based on the de novo assembly of 150 genomes from 50 family trios.

The RightMed test covers 22 genes in which variants are known to contribute to the effectiveness or safety of more than 340 drugs for more than 20 indications.

The RightMed test covers 22 genes in which variants are known to contribute to the effectiveness or safety of more than 340 drugs for more than 20 indications.

The services will couple NEB's reagents and expertise in enzyme development and manufacturing with TTP's Desktop Biology product development and engineering know-how.

Polygamy amplified a rare genetic disease in area near Arizona-Utah border, BBC Future reports.

Genetic ancestry testing led one woman to learn that her father and another baby boy had been switched at birth, the Washington Post reports.

Simple de-identification methods can protect information in a database from attackers, a new study suggests.

In Science this week: approach to visualize chromatin structure in nuclei, and more.

Whatever practices you use for NGS assay development, validation, and performance monitoring, your goal is the same: Your results must be as accurate, precise, and consistent as possible.

That goal is within reach. And in this paper, we’ll show you how. By reading this white paper, you will learn:

· Why quality control is so challenging for NGS labs

· How reference materials may be the key to quality control

· The 9 key characteristics of sufficient NGS reference materials

· How to use QC metrics to monitor the health of your NGS assays

What’s been holding back more widespread adoption of liquid biopsy testing?

Lack of adequate circulating tumor DNA reference materials for developing and measuring safe, accurate and reproducible assays has been a challenge for clinical labs

Liquid biopsies are poised to revolutionize cancer diagnosis and therapy, but until now, advances in diagnostic technology - particularly at the low end of the sample input and sensitivity spectrum - have been hampered by the lack of ability of labs to reproducibly measure and assess the assay’s performance.